Chiron Sues Corus Pharma For Stealing Trade Secrets

Law360, New York (December 8, 2004, 12:00 AM EST) -- Biotech company Chiron has sued Seattle startup Corus Pharma, which is preparing to go public, for allegedly misappropriating trade secrets underpinning the development of an inhalable drug for cystic fibrosis.

The complaint accuses Corus and two executives, including chief executive Bruce Montgomery, of violating employment agreements they worked under at Pathogenesis, which was sold to Chiron for about $700 million in August 2000.

Montgomery, the former vice president of research and development at PathoGenesis, helped Genentech Inc. develop the cystic fibrosis treatment Pulmozyme before joining the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.